Precision Pulse
Podcast Description
A thought-provoking series exploring the transformative impact of precision in health, lifestyle, and beyond. Through this podcast, our goal is to bring you conversations and insights that inspire a more intentional, precise approach to everyday life
Podcast Insights
Content Themes
The podcast explores the theme of precision across various facets of life, including health, fitness, and lifestyle choices. Episodes delve into subjects such as the role of data in enhancing well-being, the significance of mindful living, and the intersection of technology and personal health. For instance, the pilot episode features an insightful conversation with Pete Riccelli on the concept of precision beyond medicine.

A thought-provoking series exploring the transformative impact of precision in health, lifestyle, and beyond. Through this podcast, our goal is to bring you conversations and insights that inspire a more intentional, precise approach to everyday life
A lung cancer patient can have a targeted therapy available to them and never find out — because the biomarker test failed, took too long, or was never ordered. Dr. Barney Balmforth thinks that gap is an engineering problem, not a science problem.
In this episode of Precision Pulse, Amit Jain of @Precision_Pulse_with_Amit sat down with @BarneyBalmforth-Biofidelity , co-founder and CEO of @Biofidelity a molecular diagnostics company based in Cambridge, England
We talked about why comprehensive genomic profiling has become the default answer to questions that may not require it, what it takes to run guideline-recommended lung biomarker testing on PCR instruments labs already own, and why Biofidelity’s newer Enspyre technology goes after the inefficiency of sequencing itself rather than competing with it.
We also get into reimbursement and the regulatory path scenarios, the CellCarta partnership and what changed when it expanded to global exclusivity, and where Barney thinks the life sciences industry is structurally wrong right now.
— CHAPTERS —
00:00 The patients who never get tested
00:45 Welcome to Precision Pulse
02:15 From physics to cancer diagnostics
08:15 Why biomarker testing still does not reach patients
13:15 Aspyre: comprehensive lung testing on a standard PCR machine
20:15 Enspyre: the signal-to-noise problem inside sequencing
26:15 CellCarta, biopharma, and the commercial model
30:45 Near-term milestones and the five-year vision
35:15 Rapid fire
37:45 Closing thoughts
#PrecisionMedicine #Diagnostics #LungCancer #Genomics #Oncology #MolecularDiagnostics #LiquidBiopsy #NGS #CancerResearch #HealthTech #LifeSciences #Biotech #precisiononcology #podcastclips #podcast #PrecisionPulse #biofidelity #precisionpulsewithamit #lungcancerawarenessmonth #lungcancerawareness #precisionmedicine #diagnostics #lungcancersymptoms

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.